Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
ARS PharmaceuticalsJohnson & Johnson
Last price
$3.38$273.20
Currency
USD
USD
$335M$658B
-41.49
-$2.18$6.58
0.970.21
0$5.28
01.96%
Sector
HealthHealth
Employees
198138,200
Ticker
$SPRY$JNJ
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $SPRY or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.